Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup
Saved in:
Main Authors: | Jianghua Ding (Author), Shengping Gong (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways
by: María Ortiz-Estévez, et al.
Published: (2021) -
Optimizing Care for High-Risk Multiple Pregnancy with POCUS - A Case of Quadruplet Pregnancy Early Diagnosis
by: Bernardo Vidal Pimentel, et al.
Published: (2023) -
Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
by: Jingsong He, et al.
Published: (2020) -
Examining subgroup effects by socioeconomic status of public health interventions targeting multiple risk behaviour in adolescence
by: Laura Tinner, et al.
Published: (2018) -
Association of Acculturation with Cardiovascular Risk Factors in Asian-American Subgroups
by: Yuemeng LI, et al.
Published: (2023)